XML 13 R30.htm IDEA: XBRL DOCUMENT v3.20.1
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended 76 Months Ended
Feb. 13, 2018
Aug. 23, 2017
Mar. 31, 2020
Apr. 30, 2018
Jan. 31, 2018
Nov. 30, 2017
Sep. 30, 2017
Aug. 31, 2017
Mar. 31, 2016
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2010
Dec. 31, 2018
Dec. 31, 2015
Jan. 09, 2020
Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue recognized in period related to performance in prior periods                   $ 44,600,000 $ 19,600,000          
Deferred revenue, current portion     $ 3,007,000             3,007,000           $ 5,517,000
Deferred revenue, less current portion     2,554,000             2,554,000           2,554,000
Potential future additional development and regulatory milestones     1,700,000,000             1,700,000,000            
Accounts receivable     42,031,000             42,031,000           36,802,000
Revenue from Contract with Customer, Excluding Assessed Tax                   50,573,000 28,222,000          
Deferred revenue     5,561,000             5,561,000           $ 8,071,000
BMS Collaboration Agreement                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Sales Milestone Revenue     25,000,000.0             25,000,000.0            
BMS Collaboration Agreement | Bempegaldesleukin | Nektar's                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Global commercialization profits and losses sharing percentage 65.00%                              
Percentage of sharing production costs 65.00%                              
Upfront and milestone payments received from license agreements       $ 1,000,000,000.0                        
Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones                   1,450,000,000            
BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Milestone One                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Potential future additional payments for development milestones                             $ 25,000,000.0  
BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Milestone Two                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Potential future additional payments for development milestones                             25,000,000.0  
BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Milestone Three                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Potential future additional payments for development milestones                             $ 75,000,000.0  
BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Maximum                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Eligible additional cash payments receivable upon achievement of certain sales milestones       $ 350,000,000.0                        
BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Opdivo                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of sharing development costs 32.50%                              
BMS Collaboration Agreement | Bempegaldesleukin | Nektar's | Opdivo and Yervoy                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of sharing development costs 22.00%                              
NKTR-358 | Nektar's                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Received upfront and milestone payment             $ 150,000,000.0                  
Percentage of sharing in Phase 2 development costs   25.00%                            
Nektar                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of upfront payment, market access milestones, royalties and sales milestones                 40.00%              
Baxalta Incorporated/Takeda | Hemophilia                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Received under right to sublicense agreement           $ 12,000,000.0                    
Baxalta Incorporated/Takeda | Hemophilia | Annual Sales Level Milestone                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue from Contract with Customer, Excluding Assessed Tax                         $ 10,000,000.0      
Baxalta Incorporated/Takeda | Hemophilia | European Union                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue from Contract with Customer, Excluding Assessed Tax         $ 10,000,000.0                      
Bristol-Myers Squibb Company | Purchase Agreement                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Shares issued (in shares)       8,284,600                        
Sale of stock consideration received       $ 850,000,000.0                        
Bristol-Myers Squibb Company | Bempegaldesleukin | Research and Development Expense                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Reimbursement of expenses                   30,700,000 $ 28,800,000          
Bristol-Myers Squibb Company | BMS Collaboration Agreement                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Accounts receivable     31,200,000             31,200,000            
Bristol-Myers Squibb Company | BMS Collaboration Agreement | Purchase Agreement                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Total consideration received under agreements       1,850,000,000                        
Estimated fair value of shares       790,200,000                        
Remaining amount allocated to transaction price       1,059,800,000           25,000,000.0            
Potential future development, regulatory and sales milestones       $ 1,800,000,000                        
Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Global commercialization profits and losses sharing percentage 35.00%                              
Percentage of sharing production costs 35.00%                              
Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin | Opdivo                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of sharing development costs 67.50%                              
Bristol-Myers Squibb Company | BMS Collaboration Agreement | Bempegaldesleukin | Opdivo and Yervoy                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of sharing development costs 78.00%                              
Eli Lilly and Company | NKTR-358 | ASC 606                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Revenue from Contract with Customer, Excluding Assessed Tax               $ 125,900,000                
Eli Lilly and Company | NKTR-358 License                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Amount of transaction price allocated to performance obligation             125,900,000                  
Eli Lilly and Company | NKTR-358 | Maximum                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Potential future additional development and regulatory milestones   $ 250,000,000.0                            
Eli Lilly and Company | NKTR-358 | Nektar's                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of regulatory milestones payments will be reduced under certain conditions   50.00%                            
Percentage of regulatory milestones payments will be reduced if conditions occur   75.00%                            
Eli Lilly and Company | NKTR-358 | Nektar's | Maximum                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of funding phase 3 development costs on an indication by indication basis borne   25.00%                            
Eli Lilly and Company | NKTR-358 | Nektar's | Minimum                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of funding phase 3 development costs on an indication by indication basis borne   0.00%                            
Eli Lilly and Company | Phase 1 Clinical Development | NKTR-358 License                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Amount of transaction price allocated to performance obligation             17,600,000                  
Eli Lilly and Company | Drug Product Development | NKTR-358 License                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Amount of transaction price allocated to performance obligation             $ 6,500,000                  
Eli Lilly | NKTR-358                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Percentage of sharing in Phase 2 development costs   75.00%                            
Amgen, Inc.                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Received upfront and milestone payment                       $ 50,000,000.0        
Amgen, Inc. | ASC 606                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Deferred revenue     2,900,000             2,900,000            
AstraZeneca AB | MOVANTIK and MOVENTIG                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Received upfront and milestone payment                           $ 385,000,000.0    
AstraZeneca AB | AstraZeneca-Kirin                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Deferred revenue     0             0            
Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner                 60.00%              
Other                                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                                
Deferred revenue     2,000,000.0             2,000,000.0            
Potential future additional payments for development milestones     $ 40,000,000.0             $ 40,000,000.0